PasitheaLogo.png
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004
February 13, 2024 07:59 ET | Pasithea
Pasithea Tx activates four U.S. sites for Phase 1 Trial of its next-gen MEK inhibitor, aiming to assess safety, efficacy, and biomarker data.
PasitheaLogo.png
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
January 08, 2024 07:59 ET | Pasithea
Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments.
PasitheaLogo.png
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
January 02, 2024 08:35 ET | Pasithea
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
PasitheaLogo.png
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
December 19, 2023 17:19 ET | Pasithea
Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)
PasitheaLogo.png
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
December 11, 2023 08:01 ET | Pasithea
Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24.
PasitheaLogo.png
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
November 29, 2023 16:27 ET | Pasithea
Pasithea Therapeutics adjourns 2023 annual meeting of stockholders.
PasitheaLogo.png
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
November 09, 2023 07:59 ET | Pasithea
Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS
PasitheaLogo.png
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
September 14, 2023 08:30 ET | Pasithea
PALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...
PasitheaLogo.png
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 16:14 ET | Pasithea
-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com --  PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA)...
PasitheaLogo.png
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
August 01, 2023 07:59 ET | Pasithea
-- PAS-003 is a monoclonal antibody targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) --   -- Lead α5/β1 integrin drug candidate to be selected in H2 2023 --  ...